TCT, October 14 th , 2008 TCT, October 14 th , 2008 Nico H.J.Pijls, MD, PhD Nico H.J.Pijls, MD, PhD Catharina Hospital, Eindhoven Catharina Hospital, Eindhoven The Netherlands, The Netherlands, on behalf of the on behalf of the FAME investigators FAME investigators FRACTIONAL FLOW RESERVE FRACTIONAL FLOW RESERVE versus versus ANGIOGRAPHY ANGIOGRAPHY FOR GUIDING PCI IN PATIENTS WIT FOR GUIDING PCI IN PATIENTS WIT LTIVESSEL CORONARY ARTERY DISEASE LTIVESSEL CORONARY ARTERY DISEASE Late Breaking Trial at Late Breaking Trial at
34
Embed
TCT, October 14 th, 2008 Nico H.J.Pijls, MD, PhD Catharina Hospital, Eindhoven The Netherlands, The Netherlands, on behalf of the FAME investigators FRACTIONAL.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
TCT, October 14 th , 2008TCT, October 14 th , 2008
Nico H.J.Pijls, MD, PhDNico H.J.Pijls, MD, PhDCatharina Hospital, EindhovenCatharina Hospital, Eindhoven The Netherlands,The Netherlands,on behalf of the on behalf of the FAME investigatorsFAME investigators
FRACTIONAL FLOW RESERVE FRACTIONAL FLOW RESERVE versusversus ANGIOGRAPHY ANGIOGRAPHY FOR GUIDING PCI IN PATIENTS WITH FOR GUIDING PCI IN PATIENTS WITH MULTIVESSEL CORONARY ARTERY DISEASEMULTIVESSEL CORONARY ARTERY DISEASE
Late Breaking Trial atLate Breaking Trial at
FAME study: disclosureFAME study: disclosure
To perform the FAME study, an unrestrictedTo perform the FAME study, an unrestrictedinstitutional research grant was obtained from RADI institutional research grant was obtained from RADI Medical SystemsMedical Systems
I have no further conflict of interest to declareI have no further conflict of interest to declare
FFractional Flow Reserve ractional Flow Reserve
versusversus
AAngiography forngiography for
MMultivessel ultivessel
EEvaluationvaluation
FRACTIONAL FLOW RESERVE FRACTIONAL FLOW RESERVE versusversus ANGIOGRAPHY ANGIOGRAPHY FOR GUIDING PCI IN PATIENTS WITH FOR GUIDING PCI IN PATIENTS WITH MULTIVESSEL CORONARY ARTERY DISEASEMULTIVESSEL CORONARY ARTERY DISEASE
• Stenting of non-ischemic stenoses has no benefitStenting of non-ischemic stenoses has no benefit compared to medical treatment onlycompared to medical treatment only
• Stenting of ischemia-related stenoses improvesStenting of ischemia-related stenoses improves symptoms and outcomesymptoms and outcome
• In multivessel coronary disease (MVD), identifyingIn multivessel coronary disease (MVD), identifying which stenoses cause ischemia is difficult:which stenoses cause ischemia is difficult: Non-invasive tests are often unreliable in MVD andNon-invasive tests are often unreliable in MVD and coronary angiography often results in both under- coronary angiography often results in both under- or overestimation of functional stenosis severityor overestimation of functional stenosis severity
• Fractional Flow Reserve (FFR),Fractional Flow Reserve (FFR), is the most accurate is the most accurate and selective index to indicate whether a particular and selective index to indicate whether a particular stenosis is responsible for inducible ischemiastenosis is responsible for inducible ischemia
• FFR can be easily determined in the cathlabFFR can be easily determined in the cathlab just prior to stentingjust prior to stenting
Therefore:Therefore:
• FFR guidance of PCI in patients withFFR guidance of PCI in patients with multivessel disease may improve outcomemultivessel disease may improve outcome
FAME study: FAME study: HYPOTHESISHYPOTHESIS
FFR – guided Percutaneous Coronary FFR – guided Percutaneous Coronary Intervention (PCI) in multivessel disease, Intervention (PCI) in multivessel disease, is superior to current is superior to current angiography – guided PCIangiography – guided PCI
FAME study: FAME study: DESIGNDESIGN
Randomized multicenter study in 1000 patients Randomized multicenter study in 1000 patients undergoing DES-stenting for multivessel disease undergoing DES-stenting for multivessel disease in 20 US and European centersin 20 US and European centers
Multivessel disease:Multivessel disease:Stenoses of > 50% in at least 2 of the 3 Stenoses of > 50% in at least 2 of the 3 majormajorcoronary arteriescoronary arteries
• independent core-labindependent core-lab• independent data analysisindependent data analysis• blinded adverse event committeeblinded adverse event committee
Participating CentersUSA (6)USA (6)
Stanford UniversityStanford University(William F. Fearon)(William F. Fearon)
Northeast Cardiology, Bangor, Northeast Cardiology, Bangor, Maine Maine (Peter N. Ver Lee)(Peter N. Ver Lee)University of LouisvilleUniversity of Louisville(Massoud Leesar)(Massoud Leesar)
St Louis UniversitySt Louis University(Michael Lim)(Michael Lim)
University Hospital VirginiaUniversity Hospital Virginia(Michael Ragosta)(Michael Ragosta)
University of South CarolinaUniversity of South Carolina(Eric Powers)(Eric Powers)
EUROPE (14)EUROPE (14)
King´s College Hospital, London) King´s College Hospital, London) (Ph.MacCarthy)(Ph.MacCarthy)
Cardiovascular Center Aalst Cardiovascular Center Aalst (B. De (B. De Bruyne)Bruyne)
Catharina Hospital Eindhoven Catharina Hospital Eindhoven (N.Pijls)(N.Pijls)
Glasgow Western Infirmary Glasgow Western Infirmary (Keith (Keith Oldroyd)Oldroyd)
Royal Victoria Hospital, Belfast Royal Victoria Hospital, Belfast (Ganesh Manoharan)(Ganesh Manoharan)
FAME studyFAME study
Steering Committee:Steering Committee:Nico H.J. Pijls, Eindhoven, Netherlands (PI)Nico H.J. Pijls, Eindhoven, Netherlands (PI)William F. Fearon, Stanford, CA, USA (PI)William F. Fearon, Stanford, CA, USA (PI)Bernard De Bruyne, Aalst, BelgiumBernard De Bruyne, Aalst, BelgiumPim A.L. Tonino, Eindhoven, NetherlandsPim A.L. Tonino, Eindhoven, Netherlands
Data analysis:Data analysis:Uwe Siebert, Boston, MA, USA and Hall, AUwe Siebert, Boston, MA, USA and Hall, ARafaele Gothe and Bernard Bornschein, Hall, AustriaRafaele Gothe and Bernard Bornschein, Hall, Austria
Clinical Events Committee:Clinical Events Committee:Eric Eeckhout, Lausanne, SwitzerlandEric Eeckhout, Lausanne, SwitzerlandMorton Kern, Irvine, CA, USAMorton Kern, Irvine, CA, USAMamdouh El Gamal, Eindhoven, NLMamdouh El Gamal, Eindhoven, NLJohn Hodgson, Phoenix, AZ, USAJohn Hodgson, Phoenix, AZ, USAEmanuele Barbato, Naples, ItalyEmanuele Barbato, Naples, Italy
FAME study: FAME study: Study PopulationStudy Population
The FAME study was designed to The FAME study was designed to reflect daily practicereflect daily practicein performing PCI in patients in performing PCI in patients with multivessel diseasewith multivessel disease
Inclusion criteria:Inclusion criteria:• ALLALL patients with multivessel disease patients with multivessel disease• At least 2 stenoses ≥ 50% in 2 or 3 major epicardialAt least 2 stenoses ≥ 50% in 2 or 3 major epicardial coronary artery disease, amenable for stentingcoronary artery disease, amenable for stenting
Exclusion criteria:Exclusion criteria:• Left main disease or previous bypass surgeryLeft main disease or previous bypass surgery• ST-elevation MI with CK > 1000 U/l within last 5 daysST-elevation MI with CK > 1000 U/l within last 5 days• extremely tortuous or calcified coronary arteriesextremely tortuous or calcified coronary arteries
Note:Note: patients with previous PCI were not excluded patients with previous PCI were not excluded
Angiography-guided PCI FFR-guided PCI
Measure FFR in all indicated stenoses
Stent all indicated stenoses
Stent only those stenoses with FFR ≤ 0.80
Randomization
Indicate all stenoses ≥ 50% considered for stenting
Patient with stenoses ≥ 50% in at least 2 of the 3 major
Composite of death, myocardial infarction, Composite of death, myocardial infarction, or repeat revascularization (“MACE”) or repeat revascularization (“MACE”) at 1 year at 1 year
• individual components of MACE at 1 yearindividual components of MACE at 1 year• functional classfunctional class• use of anti-anginal drugsuse of anti-anginal drugs• health-related quality of life (EuroQOL-5D)health-related quality of life (EuroQOL-5D)
• procedure timeprocedure time• amount of contrast agent used during procedureamount of contrast agent used during procedure• cost of the procedurecost of the procedure
Assessed for eligibilityN=1905
Angiography-guided PCI
N=496
FFR-guided PCIN=509
Lost to follow-upN=8
AnalyzedN=496
AnalyzedN=509
RandomizedN=1005
Lost to follow-upN=11
Not eligible N= 900
Left main stenosis N= 157
Extreme coronary tortuosity
or calcification N= 217
No informed consent N= 105
Contra-indication for DES N= 86
Participation in other study N= 94
Logistic reasons N= 210
Other reasons N= 31
CONSORT-E CHART
• PCI according to local routinePCI according to local routine• Only drug-eluting stents (DES)Only drug-eluting stents (DES)• FFR measured by Pressure WireFFR measured by Pressure Wire
((Certus wire, RADI Medical SystemsCertus wire, RADI Medical Systems))• hyperemia induced by i.v. adenosine 140 µg/kg/min hyperemia induced by i.v. adenosine 140 µg/kg/min
in femoral veinin femoral vein• EKG, CK, CK-MB, etc during hospital stayEKG, CK, CK-MB, etc during hospital stay• Follow-up at 1 month, 6 months, 1 yearFollow-up at 1 month, 6 months, 1 year• Also in case of repeat-procedure , strictly adherence Also in case of repeat-procedure , strictly adherence
Routine measurement of FFR during PCI with DES Routine measurement of FFR during PCI with DES in patients with multivessel disease, when in patients with multivessel disease, when compared to current angiography guided strategycompared to current angiography guided strategy
• reduces the rate of the composite endpoint of reduces the rate of the composite endpoint of
death, myocardial infarction, re-PCI and CABG death, myocardial infarction, re-PCI and CABG
at 1 year by at 1 year by ~ ~ 30%30%
• reduces mortality and myocardial infarction at reduces mortality and myocardial infarction at
Routine measurement of FFR during PCI with DES Routine measurement of FFR during PCI with DES in patients with multivessel disease, when in patients with multivessel disease, when compared to current angiography guided strategy,compared to current angiography guided strategy,furthermore:furthermore:
• is cost-saving and does not prolong the procedureis cost-saving and does not prolong the procedure
• reduces the number of stents usedreduces the number of stents used
• decreases the amount of contrast agent useddecreases the amount of contrast agent used
• results in a similar, if not better, functional statusresults in a similar, if not better, functional status
Routine measurement of FFR during DES-stenting Routine measurement of FFR during DES-stenting in patients with multivessel disease is superior in patients with multivessel disease is superior to current angiography guided treatment.to current angiography guided treatment.
It improves outcome of PCI significantlyIt improves outcome of PCI significantly
It supports the evolving paradigm of It supports the evolving paradigm of
“ “Functionally Complete Revascularization”,Functionally Complete Revascularization”, i.e. stenting of ischemic lesions and i.e. stenting of ischemic lesions and medical treatment of non-ischemic ones.medical treatment of non-ischemic ones.